Biogen (NASDAQ:BIIB) and Genenta Science (NASDAQ:GNTA) Critical Survey

Genenta Science (NASDAQ:GNTA) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Institutional & Insider Ownership

15.1% of Genenta Science shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 29.0% of Genenta Science shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Genenta Science and Biogen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Biogen	13.81%	12.83%	8.01%

Analyst Recommendations

This is a summary of recent ratings and target prices for Genenta Science and Biogen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1	0	0	0	1.00
Biogen	2	12	16	1	2.52

Biogen has a consensus target price of $218.15, suggesting a potential upside of 9.54%. Given Biogen’s stronger consensus rating and higher probable upside, analysts plainly believe Biogen is more favorable than Genenta Science.

Volatility & Risk

Genenta Science has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500.

Valuation and Earnings

This table compares Genenta Science and Biogen”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39 million	N/A	N/A
Biogen	$9.89 billion	2.97	$1.29 billion	$9.32	21.37

Biogen has higher revenue and earnings than Genenta Science.

Summary

Biogen beats Genenta Science on 10 of the 12 factors compared between the two stocks.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin’s lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin’s lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer’s disease and dementia, neuromuscular disorders, Parkinson’s disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.